Heng Li1, Yucong Zhang2, Dong Li3, Xin Ma4, Kai Xu5, Beichen Ding6, Hongzhao Li4, Zhize Wang7, Wei Ouyang1, Gongwei Long1, Jin Zeng8, Haoran Liu1, Libin Yan7, Yangjun Zhang1, Zheng Liu1, Wei Guan1, Zhiquan Hu1, Cong Liu9, Jie Wan9, Guoping Wang9, Xiaoyong Pu10, Minghui Zhang10, Linlang Guo11, Ruihua An6, Jiping Qi12, Aitao Guo13, Zhangqun Ye1, Jiumin Liu3, Xu Zhang4, Hua Xu14. 1. Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China. 2. Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 4. Department of Urology, Chinese PLA General Hospital, Beijing, China. 5. Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, China. 6. Department of Urology, the First Affiliated Hospital of Harbin Medical University, Harbin, China. 7. Department of Urology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. 8. Department of Urology, the First Affiliated Hospital of Nanchang University, Nanchang, China. 9. Department of Pathology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 10. Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 11. Department of Pathology, Zhujiang Hospital of Southern Medical University, Guangzhou, China. 12. Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin, China. 13. Department of Pathology, Chinese PLA General Hospital, Beijing, China. 14. Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China. Electronic address: xuhuawhu@163.com.
Abstract
BACKGROUND: Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored. OBJECTIVE: To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining was used to assess AR-V7 protein expression in biopsy tissues collected before initiation of ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate associations of AR-V7 status (positive vs negative) with progression-free survival (PFS) and overall survival (OS). RESULTS AND LIMITATIONS: Sixty-four (21%) patients were AR-V7-positive and 246 (79%) patients were AR-V7-negative. The median follow-up for patients not confirmed dead was 25 mo (interquartile range 10-30). Compared to AR-V7-negative patients, AR-V7-positive patients had significantly shorter PFS (hazard ratio [HR] 47.39, 95% confidence interval [CI] 25.83-86.94) and OS (HR 3.57, 95% CI 1.46-8.72). In multivariable analysis, AR-V7 was an independent predictive factor (HR 7.61, 95% CI 5.24-11.06) for shorter PFS. Limitations include the sample size and follow-up period. CONCLUSIONS: AR-V7 expression in primary cancer tissue is correlated with poor prognosis for mHSPC patients receiving ADT. PATIENT SUMMARY: In this study of men with metastatic hormone-sensitive prostate cancer, AR-V7 protein expression in primary cancer tissue was associated with poor outcomes on androgen deprivation therapy.
BACKGROUND: Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored. OBJECTIVE: To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining was used to assess AR-V7 protein expression in biopsy tissues collected before initiation of ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate associations of AR-V7 status (positive vs negative) with progression-free survival (PFS) and overall survival (OS). RESULTS AND LIMITATIONS: Sixty-four (21%) patients were AR-V7-positive and 246 (79%) patients were AR-V7-negative. The median follow-up for patients not confirmed dead was 25 mo (interquartile range 10-30). Compared to AR-V7-negative patients, AR-V7-positive patients had significantly shorter PFS (hazard ratio [HR] 47.39, 95% confidence interval [CI] 25.83-86.94) and OS (HR 3.57, 95% CI 1.46-8.72). In multivariable analysis, AR-V7 was an independent predictive factor (HR 7.61, 95% CI 5.24-11.06) for shorter PFS. Limitations include the sample size and follow-up period. CONCLUSIONS: AR-V7 expression in primary cancer tissue is correlated with poor prognosis for mHSPC patients receiving ADT. PATIENT SUMMARY: In this study of men with metastatic hormone-sensitive prostate cancer, AR-V7 protein expression in primary cancer tissue was associated with poor outcomes on androgen deprivation therapy.
Authors: Johann S de Bono; Adam Sharp; Adam G Sowalsky; Ines Figueiredo; Rosina T Lis; Ilsa Coleman; Bora Gurel; Denisa Bogdan; Wei Yuan; Joshua W Russo; John R Bright; Nichelle C Whitlock; Shana Y Trostel; Anson T Ku; Radhika A Patel; Lawrence D True; Jonathan Welti; Juan M Jimenez-Vacas; Daniel Nava Rodrigues; Ruth Riisnaes; Antje Neeb; Cynthia T Sprenger; Amanda Swain; Scott Wilkinson; Fatima Karzai; William L Dahut; Steven P Balk; Eva Corey; Peter S Nelson; Michael C Haffner; Stephen R Plymate Journal: Clin Cancer Res Date: 2022-08-15 Impact factor: 13.801
Authors: G Francolini; M Loi; V Salvestrini; M Mangoni; B Detti; V Di Cataldo; M Aquilano; P Pinzani; F Salvianti; I Desideri; M Mariotti; P Garlatti; G Stocchi; L P Ciccone; S Lucidi; G Salvatore; M Sottili; I Meattini; L Livi Journal: Clin Exp Metastasis Date: 2021-08-19 Impact factor: 5.150
Authors: Paul Basil; Matthew J Robertson; William E Bingman; Amit K Dash; William C Krause; Ayesha A Shafi; Badrajee Piyarathna; Cristian Coarfa; Nancy L Weigel Journal: Sci Rep Date: 2022-03-30 Impact factor: 4.379
Authors: Biagio Barone; Luigi Napolitano; Marco Abate; Luigi Cirillo; Pasquale Reccia; Francesco Passaro; Carmine Turco; Simone Morra; Francesco Mastrangelo; Antonio Scarpato; Ugo Amicuzi; Vincenzo Morgera; Lorenzo Romano; Francesco Paolo Calace; Savio Domenico Pandolfo; Luigi De Luca; Achille Aveta; Enrico Sicignano; Massimiliano Trivellato; Gianluca Spena; Carlo D'Alterio; Giovanni Maria Fusco; Raffaele Vitale; Davide Arcaniolo; Felice Crocetto Journal: Int J Mol Sci Date: 2022-03-24 Impact factor: 5.923